Anticoagulation in atrial fibrillation: NOAC's the word

Affiliations

Editorial

Karl Werdan et al. Dtsch Arztebl Int. 2013 Aug.

. 2013 Aug;110(31-32):523-4.

doi: 10.3238/arztebl.2013.0523.

¹ Department of Medicine III, Department of Medicine and Heart Centre, University Hospital of Halle(Saale).

No abstract available

Comment on

The perioperative management of treatment with anticoagulants and platelet aggregation inhibitors.
Schlitt A, Jámbor C, Spannagl M, Gogarten W, Schilling T, Zwissler B. Schlitt A, et al. Dtsch Arztebl Int. 2013 Aug;110(31-32):525-32. doi: 10.3238/arztebl.2013.0525. Epub 2013 Aug 5. Dtsch Arztebl Int. 2013. PMID: 24069073 Free PMC article. Review.

1. ESC Working Group on Thrombosis—Task Force on Anticoagulants in Heart Disease Position Paper. New Oral Anticoagulants in Atrial Fibrillation and Acute Coronary Syndromes. J Am Coll Cardiol. 2012;59:1413–1425. - PubMed
1. Dentali F, Riva N, Crowther M, et al. Efficacy and Safety of the Novel Oral Anticoagulants in Atrial Fibrillation—A Systematic Review and Meta-Analysis of the Literature. Circulation. 2012;126:2381–2391. - PubMed
1. Matchar DB, Jacobson A, Dolor R, et al. for the THINRS Executive Committee and Site Investigators. Effect of Home Testing of International Normalized Ratio on Clinical Events. N Engl J Med. 2010;363:1608–1620. - PubMed
1. Clarkesmith DE, Pattison HM, Lane DA. Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation. Cochrane Database Syst Rev. 2013;6 CD008600. [Epub ahead of print] - PubMed
1. Anonymus. Vitamin-K-Antagonisten oder „neue“ orale Antikoagulanzien? [Vitamin K antagonsits or ’new’ oral anticoagulants?] Der Arzneimittelbrief. 2013;47:40DB01–40DB02.